{"id":9919,"date":"2009-11-01T06:12:02","date_gmt":"2009-11-01T06:12:02","guid":{"rendered":"http:\/\/cardiophile.org\/?p=3382"},"modified":"2009-11-01T06:12:02","modified_gmt":"2009-11-01T06:12:02","slug":"antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/","title":{"rendered":"Antiplatelet drug resistance and newer antiplatelet agents"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Antiplatelet drug resistance and newer antiplatelet agents<\/span><\/h2>\n<p>Antiplatelet drug resistance and newer antiplatelet agents:<\/p>\n<p><strong>Aspirin resistance<\/strong><\/p>\n<p>Aspirin resistance identified in 1978, initially in patients undergoing cardiac catheterisation and later in stroke patients. Prior aspirin use has been identified as a risk factor in those presenting with acute coronary syndrome. This means that they have aspirin resistance.<br \/>\nBleeding time, flow cytometry, light transmittance aggregometry are some of the measures to assess aspirin resistance. Light transmittance aggregometry is the most useful method. This depends on whether platelet plugs are formed or not. If platelet plugs are formed, they settle down and allow light transmission. This indicates residual platelet function and hence aspirin resistance. The various assays vary between them and with clinical correlation. Hence the clinical utility of assays still remain doubtful.<br \/>\nEliminating the interfering substances like ibuprofen may decrease the resistance. Non-enteric coated preparations are better than enteric coated ones, though the more commonly used one is the later. Combining with other antiplatelet agents is useful in overcoming aspirin resistance.<\/p>\n<p><strong>Clopidogrel resistance<\/strong><\/p>\n<p>There is a wide variation in individual responsiveness to clopidogrel. There are non-responders and semi-responders. Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance. Atorvastatin \u2013 clopidogrel interaction has also to be considered, though the clinical significance of the interaction has not been established.<\/p>\n<p><strong>Newer antiplatelet agents<\/strong><\/p>\n<p>Prasugrel, Cangrelor and Ticagrelor are the newer agents. Prasugrel and Ticagrelor are oral agents while Cangrelor is a parenteral agent. TRITON TIMI 38 trial compared prasugrel with clopidogrel found prasugrel to be more effective, but with a slightly higher bleeding risk. Stent thrombosis was significantly lower with prasugrel. Platelet inhibition is much superior with prasugrel, compared with clopidogrel. PLATO (NEJM, September 2009) compared Ticagrelor vs Clopidogrel and showed the former to be more effective with no significant increase in bleeding. Prasugrel has been approved by FDA, with a warning on the label regarding the potential small risk of fatal bleeding noted in some studies.<\/p>\n<p>Clinical role of assessment of aspirin resistance in the setting of PCI<br \/>\nIncreased risk of stent thrombosis occurs with resistance and detection by pre procedure testing may indicate use of additional glycoprotein IIb\/IIIa receptor blockers in the setting of PCI.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.<\/p>\n","protected":false},"author":1,"featured_media":38673,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-9919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antiplatelet drug resistance and newer antiplatelet agents<\/title>\n<meta name=\"description\" content=\"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antiplatelet drug resistance and newer antiplatelet agents\" \/>\n<meta property=\"og:description\" content=\"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2009-11-01T06:12:02+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Antiplatelet drug resistance and newer antiplatelet agents\",\"datePublished\":\"2009-11-01T06:12:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/\"},\"wordCount\":373,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/\",\"name\":\"Antiplatelet drug resistance and newer antiplatelet agents\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2009-11-01T06:12:02+00:00\",\"description\":\"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antiplatelet drug resistance and newer antiplatelet agents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antiplatelet drug resistance and newer antiplatelet agents","description":"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/","og_locale":"en_US","og_type":"article","og_title":"Antiplatelet drug resistance and newer antiplatelet agents","og_description":"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.","og_url":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2009-11-01T06:12:02+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Antiplatelet drug resistance and newer antiplatelet agents","datePublished":"2009-11-01T06:12:02+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/"},"wordCount":373,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/","name":"Antiplatelet drug resistance and newer antiplatelet agents","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2009-11-01T06:12:02+00:00","description":"Antiplatelet drug resistance: Females, those with metabolic syndrome and high triglyceride levels are known to have higher clopidogrel resistance.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/antiplatelet-drug-resistance-and-newer-antiplatelet-agents-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Antiplatelet drug resistance and newer antiplatelet agents"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/9919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=9919"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/9919\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=9919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=9919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=9919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}